Navigation Links
Amira Announces AM103 and AM803 Patent Grant in the United Kingdom

SAN DIEGO, July 13 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

In January 2008, Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement allowing GSK to develop, manufacture and commercialize specified FLAP inhibitors for the treatment of respiratory and cardiovascular disease.  AM803 was added to the license agreement later in 2008.  GSK is currently conducting Phase 2 clinical trials in respiratory disorders with an Amira-licensed FLAP inhibitor.

"Amira continues to be successful in obtaining patent coverage for compounds being advanced in clinical trials," said John Hutchinson, Ph.D., Vice President of Chemistry.  "This patent covering both AM103 and AM803 is the third issued this year, following two patents related to our DP2 receptor antagonists granted by the United Kingdom."  Bob Baltera, Chief Executive Officer of Amira, added, "This patent relates to some of the first compounds developed by Amira.  It reflects our ongoing objective to secure strong patent protection around each of our development programs."

The newly granted claims cover novel inhibitors of the FLAP protein.  The patent also discloses uses of FLAP inhibitors for the treatment of inflammatory diseases such as asthma, cardiovascular disease, dermatological disorders and ocular diseases.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®.  The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
2. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
3. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
4. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
5. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
6. Hanger Orthopedic Group, Inc. Announces Second Quarter 2010 Earnings Release Conference Call
7. K-V Pharmaceutical Announces Resubmission to New Drug Application for Gestiva™
8. Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting
9. Medical Alarm Concepts™ Announces Roll-Out of the MediPendant™ at Albertsons
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):